NexgenRx Reports Q3 Growth and Announces Dividend

NexgenRx Inc. revealed its financial outcomes for the third quarter ending September 30, 2024. The company reported a notable rise in revenue, reaching $4,158,667, marking a 22.67% increase from the prior year. The growth was largely attributed to an upsurge in transaction and administration revenue, alongside the introduction of Software as a Service (SaaS) solutions.

EBITDA also saw an improvement, increasing to $446,448, representing a $260,825 rise from Q3 2023. NexgenRx declared a dividend of $0.005 per share, benefitting holders of common and series 1 preferred shares, payable by December 20, 2024.

With a solid cash position of $1,844,669, the company remains financially stable. As the common shares continue trading under the symbol 'NXG', the dividend aligns with NexgenRx's growth strategy and commitment to shareholder returns.